Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers

INTRODUCTION: Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-related peptide pathway, was approved by the US Food and Drug Administration in 2018 for the prevention of migraine in adults. There is limited data available on its impact in real-world settings. The study ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Faust, Elizabeth, Pivneva, Irina, Yang, Karen, Betts, Keith A., Ahmed, Zubair, Joshi, Shivang, Hogan, Rebecca, Blumenfeld, Andrew, Schim, Jack, Feoktistov, Alexander, Carnes, Kenneth, Bensink, Mark, Wu, Eric Q., Chou, Denise E., Chandler, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140045/
https://www.ncbi.nlm.nih.gov/pubmed/33856626
http://dx.doi.org/10.1007/s40120-021-00245-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140045/
https://www.ncbi.nlm.nih.gov/pubmed/33856626
http://dx.doi.org/10.1007/s40120-021-00245-4

Ejemplares similares